Text Size

LACTOPRES:Study on the Effect of Dairy Peptides on Blood Pressure in Untreated Hypertensive Subjects.

This study has been completed.
Sponsor:
Collaborator:
Unilever R&D
Information provided by:
Wageningen University
ClinicalTrials.gov Identifier:
NCT00167869
First received: September 12, 2005
Last updated: May 23, 2008
Last verified: May 2008
History of Changes
  Purpose

Hypertension is an increasingly important medical and public health issue. Literature suggests that there may be a role for dairy foods in the prevention and treatment of hypertension. Recently, it has been suggested that several peptides in milk proteins could have blood pressure lowering properties. LACTOPRES is a randomised, double-blind parallel trial to assess the blood pressure effect of an increased intake of dairy peptides in humans.


Condition Intervention Phase
Hypertension
 Behavioral: dairy peptides
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: LACTOPRES:Study on the Effect of Dairy Peptides on Blood Pressure in Untreated Hypertensive Subjects.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Wageningen University:

Primary Outcome Measures:
  • Blood pressure

Estimated Enrollment: 135
Study Start Date: June 2004
Study Completion Date: June 2005
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   35 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • systolic blood pressure >= 140 mmHg
  • BMI between 18 and 32 kg/m2
  • apparently healthy

Exclusion Criteria:

  • antihypertensive medication
  • medically prescribed or slimming diet
  • lactating, pregnant
  • irregular pulse
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00167869

Locations
Netherlands
Wageningen University, Division of Human Nutrition
Wageningen, Netherlands, 6700 EV
Sponsors and Collaborators
Wageningen University
Unilever R&D
Investigators
Principal Investigator: Frans J Kok, PhD Wageningen University - Division of Human Nutrition
  More Information

Additional Information:
Division of Human Nutrition, Wageningen University  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00167869     History of Changes
Other Study ID Numbers: METC-WU 04/04
Study First Received: September 12, 2005
Last Updated: May 23, 2008
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Wageningen University:
hypertension
blood pressure
dairy peptides
bioactive peptides
randomized controlled trial

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on June 18, 2013